TriSalus Life Sciences, Inc.
No enriched coverage for $TLSI in the last 7 days.
No SEC Form 4 filings for $TLSI in the last 30 days.
See all $TLSI insider activity →Analysts initiated coverage on several companies: StoneX started HOOD with a Buy and $170 target, HC Wainwright began TLSI with a Buy and $11 target, Needham initiated KDK with a Buy and $8 target, BMO rated DECK Underperform with a $70 target, and Cantor Fitzgerald gave SGMT an Overweight rating.
TriSalus Life Sciences, Inc. (TLSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. TriSalus Life Sciences Reports Second Quarter 2026 Results Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration Maintains 2026 revenue guidance of $54 million to $57 million Hosting Conferen
The provided text does not include substantive details about TriSalus Life Sciences, Inc. (TLSI) or any investigation. It only contains a disclaimer directing readers to contact the company listed in the press release for questions and stating that PR-inside is not responsible for the content.
Recent TLSI coverage spans financial news, earnings and regulation.
Coverage could lift the low‑priced stock as investors reassess valuation.
The update is a fresh earnings-and-guidance datapoint with cash runway commentary, likely driving near-term sentiment around commercial ramp and burn rate.
Investigation headlines can increase downside risk via regulatory/legal costs, delays, or adverse findings affecting operations and investor sentiment.
The announcement highlights TriSalus Life Sciences' advancements in liver and uterine therapies using the PEDD platform, which could positively influence investor sentiment and stock performance.
The article indicates a bearish sentiment for TLSI, highlighting recent stock performance and analyst ratings.
AlphAI scores every news story that mentions TLSI with an AI model for sentiment and relevance, and aggregates insider trades from TriSalus Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts initiated coverage on several companies: StoneX started HOOD with a Buy and $170 target, HC Wainwright began TLSI with a Buy and $11 target, Needham initiated KDK with a Buy and $8 target, BMO rated DECK Underperform with a $70 target, and Cantor Fitzgerald gave SGMT an Overweight rating.
1 min readTriSalus Life Sciences, Inc. (TLSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. TriSalus Life Sciences Reports Second Quarter 2026 Results Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration Maintains 2026 revenue guidance of $54 million to $57 million Hosting Conferen
6 min readThe provided text does not include substantive details about TriSalus Life Sciences, Inc. (TLSI) or any investigation. It only contains a disclaimer directing readers to contact the company listed in the press release for questions and stating that PR-inside is not responsible for the content.
2 min readTriSalus Life Sciences (TLSI) will present new clinical and preclinical data at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The presentations will highlight the capabilities of its Pressure Enabled Drug Delivery (PEDD) platform for applications in liver-directed therapies and uterine artery embolization, demonstrating the platform's versatility in enhancing therapeutic delivery across various disease states. The company's CEO, Mary Szela, and CMO, Richard Marshall, emphasized the growing body of evidence supporting PEDD's potential to improve patient outcomes by enabling more effective delivery of therapies.
3 min readThis article provides a detailed financial overview of TriSalus Life Sciences, Inc. (TLSI), including its stock price performance, key financial metrics, upcoming earnings, and analyst ratings. It describes the company's business in oncology, focusing on its integration of treatments for liver and pancreatic tumors, and offers answers to frequently asked questions about its stock and financial health.
4 min readImage source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readTriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -464.71% and +0.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readTriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -22.73% and +5.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
